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ABSTRACT 
BACKGROUND: 
Bipolar affective disorder patients, a major mental illness continues to be a 
distressing disorder.  Lithium carbonate and divalproate sodium remains FDA 
approved. Studies on its long term outcome, adherence to medication, adverse effects 
remains less. 
OBJECTIVE: 
 To evaluate the time for any mood episodes(mania/depression/mixed 
episodes). 
 To access the severity of the mood episodes. 
 To evaluate for episodes of deliberate self harm. 
 To compare the adherence between lithium and divalproate sodium group. 
 To compare the adverse effect  profile  between the two groups. 
 To access the  functioning  between the two study groups. 
 To correlate the new onset manic /depressive episode with serum 
lithium/dosage of divalproate sodium. 
 METHODOLOGY: 
We recruited 52 patients each on lithium and Divalproate arm, who qualified 
for inclusion & exclusion criteria. These patients were followed up for one year in 
psychiatry OP (initial evaluation 3
rd
 ,later 6
th
 ,9
th
 ,12
th
 month periodic evaluation). 
Socio-demographic details, severity of mood disorders, adherence of 
medications, adverse effects and functioning were accessed. 
RESULTS: 
The socio-demographic variables did not differ between the two groups. The 
confounding variables (age of onset, number of episodes, previous hospitalisations, 
polarity of previous episodes, use of psychotrophics) did not differ between the two 
groups. 
The duration of mood stabiliser was for a longer period in lithium group. 
Patients on lithium, on prolonged follow up had less frequent & less severe   
manic episode, less suicidal risk(trending towards significance). 
CONCLUSION: 
There was no difference in terms of frequency of depressive episode, 
adherence, adverse effects and global functioning between the two groups. But 
lithium group patients had lesser manic episodes, less severe episodes and low 
suicidal risk , favouring Lithium to be a better mood stabilizer. 
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INTRODUCTION 
 BPAD is one of the most disabling mental illness affecting most 
productive period of life at the age 15-45years.
1
Lithium carbonate 
is a gold standard treatment for past five decades. It has a narrow 
therapeutic index and significant adverse effects
2
.  
 Anticonvulsants (divalproate sodium, carbamazapine & 
oxcarbazapine),  proposed as an alternative, as more adverse effect 
profile and there comparative efficacy with lithium is uncertain.
3-8
 
 Lithium Carbonate being a gold standard mood stabilizer is a 
superior agent to reduce the risk of relapse and to prevent suicidal 
behaviours
(2-7).
In view of its adverse effects tolerance becomes an 
issue, which can interfere with adherence.
(4-7)
 
 Anticonvulsants ,approved by FDA, has the next level of evidence 
as a mood stabilizer but there long term safety and efficacy is 
incomparision with Lithium remains uncertain.
(7)
 
 Lithium causes multiple skin reactions the most common are acne 
and psoriasis.
(9)
 
 The prevalence of  skin reaction with lithium ranges between 3-
34%.
(9) 
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 A study shows high chances of discontinuation of lithium is due to 
adverse skin reactions. 
 Randomised controlled trails have shown superiority of 
Divalproate sodium to placebo.
(10-11)
 
 Divalproate sodium has been comparable with Lithium in Manic 
episode.
(11)
 
 FDA approved mood stabilisers for the treatment of bipolar 
affective disorder are lithium, divalproate sodium, carbamazepine 
and lamotrigine.
(17-20)
 
 Mood stabiliser can also be  used as monotherapy which was 
approved by FDA.
(21-22)
 
 Mania with two or more episodes of depression showed a good 
improvement with divalproate sodium than lithium.
(23-24)
 
 Lithium and divalproate sodium showed more effect than any other 
mood stabiliser during acute mania phase and maintenance 
phase.
(25-27)
 
 Olanzapine, risperidone, quetiapine are FDA approved atypical 
antipsychotics for the acute phase of mania.
(17,18,20)
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 Olanzapine is approved for maintenance monotherapy in bipolar 
patients. 
 Quetiapine is used for both bipolar depression and maintenance 
therapy along with divalproate sodium and lithium. 
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REVIEW OF LITRATURE 
 According to BALANCE study both lithium monotherapy and 
combination therapy with lithium and divalproate sodium are more 
likely to prevent relapse than divalproate  sodium monotherapy, 
irrespective of baseline severity of illness and is maintained for 
upto 2years
12
. 
 Bowden et al, in his randomized placebo controlled 12months trial 
Lithium v/s Divalproate sodium, has shown no significant 
difference between the two groups in terms of time to recurrence of 
mood episode during maintenance therapy 
10
 . 
 Compared to placebo, Divalproate sodium has lesser 
discontinuation rate
(13).
 
  Even though open labelled trails favours Divalproate sodium , in 
reducing the frequency and intensity of further episodes, there are 
less comparative study with Lithium in maintenance therapy.
(14-16)
   
 In a study by Martin Alda et al ,  Lithium was appreciated as a 
standard  of comparison  for long term treatment of BPAD
(47)
 .  
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 Majority of the guidelines insist to continue the same drug used in 
acute treatment for maintenance therapy , unless side-effects 
profile preclude its long-term usage 
( 48-53 )
 . 
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RATIONALE: 
 Long term outcomes are often poor in patients with bipolar 
disorder despite treatment, more effective treatments are needed to 
reduce recurrences and morbidity. 
 Hence, we proposed a prospective, comparative study between 
lithium and divalproate sodium in euthymic BPAD patients for a 
period of atleast 1year during the maintenance phase. 
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AIM  
 To compare mood stabilizing effect of lithium and divalproate 
sodium in euthymic BPAD patients. 
 
OBJECTIVE: 
 To evaluate the time for any mood 
episodes(mania/depression/mixed episodes). 
 To access the severity of the mood episodes. 
 To evaluate for episodes of deliberate self harm. 
 To compare the adherence between lithium and divalproate sodium 
group. 
 To compare the adverse effect  profile  between the two groups. 
 To access the  functioning  between the two study groups. 
 To correlate the new onset manic /depressive episode with serum 
lithium/dosage of divalproate sodium. 
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METHODOLOGY 
Primary outcome: 
 To evaluate the time for any mood episodes(mania/depression/mixed 
episodes). 
 
Secondary outcome: 
1. To access the severity of the mood episodes. 
2. To evaluate for episodes of deliberate self harm. 
3. Adherence to study treatment. 
4. Adverse effects of medications. 
5. Global assessment of functioning 
6. Comparison of suicidal risk between lithium and divalproate 
sodium patients. 
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INCLUSION CRITERIA 
1. Men and women, age 18years and above who received clinical 
diagnosis of BPAD (as per DSM criteria),by a qualified 
psychiatrist in PSG hospital in psychiatry OP. 
2. Patients were initiated, continued or restarted on a single mood 
stabilizer either on lithium or divalproate sodium by the consultant 
psychiatrist (acute episode/maintenance treatment). 
3. Patient who remains euthymic for next 2months period from the 
initiation, continuation/restarting of lithium or divalproate sodium. 
4. Patients willing for written informed consent. 
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EXCLUSION CRITERIA 
1. Patients who are already on more than one mood stabilizers during 
index diagnosis by the consultant. 
2. Presence of any uncontrolled systemic disorders. 
3. Patient not willing for informed consent. 
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FLOWCHART 1: Describing the methodology 
 
 
  
 
 
 
 
 
 
                                           
 
 
 
 
 
 
 
 
 
 
 
  
BPAD Patients initial 
diagnosed by primary therapist 
2 months 
Euthymic BPAD Patients  
52 patients on Lithium arm  
52 patients on Divalproate                    
sodium arm 
Periodic evaluation (3
rd
, 6
th
, 9
th
 & 12
th
 
month – SCID, modified SAD persons 
GAF, ADR lithium level,divalproex 
dosage monitoring) 
 
diagnosed by primary therapist 
Initial evalution (semistructured profroma 
SCID, modified SAD persons, GAF, 
YMRS, HAM-D 
Periodic evaluation (3
rd
, 6
th
, 9
th
 & 12
th
 
month – SCID, modified SAD persons 
GAF, ADR,lithium level,divalproex 
dosage monitoring) 
Initial evalution (semi structured 
profroma SCID, modified SAD persons, 
GAF, YMRS, HAM-D 
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 After recruiting the patients as per our inclusion and exclusion 
criteria, 52 patients who were on lithium therapy and 52 patients 
who were on divalproate therapy(acute episode/maintenance 
therapy),were prospectively followed up for 1year period in 
psychiatry Out Patient Department at PSG institute of medical 
science and research Coimbatore. 
 Patients were evaluated by the investigator, following 2months of 
euthymic period(index evaluation). 
 During follow up patients were evaluated at 3rd ,6th,9th and 12th  
month respectively(periodic evaluation). 
 No interventions are done in our study as it is an observational 
study. 
 Patient who are missing on follow up are contacted through 
telephone and requested to come for follow up and assessed, if 
necessary. 
 During initial  evaluation ,a semi-structured proforma  (socio-
demographic details and other confounding variables) is  
administered. Euthymic status of the patient is ensured by applying 
a SCID version for mood disorder.  Severity of suicidal ideas is 
13 
 
assessed by Modified SADPERSONS Scale. Global Assessment of  
Functioning, was assessed using a GAF  scale. 
 The dosage of the mood stabilizer could be altered by the primary 
therapist based on serum concentration of the drug/adverse effects, 
during 1year maintenance period. 
 Participants who remain on the allotted treatment for 1year of 
study. 
 Use of other psychotropics are allowed during the study trial 
(antipsychotics ,benzodiazepines). 
 During  periodic evaluation the following are accessed: 
      1.   Confounding variables. 
2. SCID-mood disorder sub-scale. 
 
3. YMRS. 
 
4. HAM-D . 
 
5. Modified SADPERSONS scale-to assess suicidal score. 
6. Adverse drug reaction. 
7. Global assessment of functioning (GAF)scale. 
8. Serum lithium level 
9. Dosage of divalproate sodium. 
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Category of  Socio-demographic details: 
1) The age was categorized into three groups: 
  18-40years- early adulthood 
40-60years- late adulthood  
>60years- geriatric group.  
 2) Education level was categorized into four groups: 
  Illiterate 
  Upto 10
th
 std 
11
th
 -12
th
 std 
Graduates.  
3) Marital status was categorized into five groups: 
Unmarried 
Married  Living together 
Married and living separately 
  Married- legally divorced 
Widow or widower. 
Category of  Confounding  variables:  
1) Age of onset of illness was categorized into four groups: 
Childhood<18years  
18-40years-early adulthood  
40-60years-Late adulthood 
Geriatric >60years. 
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2) Number of  previous episodes was categorized into four groups: 
  No episodes,  
One episode,  
Two episode, 
  >=3 episodes. 
 
3) Previous hospitalizations was categorized into four groups: 
  No hospitalization, 
  One hospitalization,  
Two hospitalizations, 
  >=3  hospitalisations. 
 
4) Polarity of episodes was categorized into seven groups: 
 No episode, 
 1Depressive episode, 
 1 Manic episode,  
Depression=Mania, 
 Depression>Mania, 
 Mania>Depression,  
>=2 Manic episodes. 
 
5) The psychotrophics given was categorized into five groups: 
 No drugs, 
 Typical antipsychotics, 
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 Atypical antipsychotics, 
 Antidepressants,  
Benzodiazepines. 
 
Category  of  Mood  stabilizers: 
The duration of  use of  mood stabilizer was categorized into four groups: 
 <6months,  
6months-1year,  
1year-2year,  
>2years. 
 
Rating Scales: 
1) Young Mania Rating Scale(YMRS) was categorized into three  
            groups:  
No mania  
Mild to Moderate 
Severe 
2) Hamilton depression rating scale (HAMD)was categorized into 
three groups: 
           No depression 
           Moderate  
           Severe 
17 
 
3) Suicidal Risk Scale(SADS) was categorized into three groups: 
 No risk 
Moderate risk 
Severe risk 
4) Adverse Drug Effect(ADR) was categorized into three groups : 
No  drug reaction  
Minimal drug reaction 
More drug reaction 
5) Global Assessment Functioning(GAF) was categorized from 0-3 
based on scores: 
  Good   (90-100) 
Mild impairment (60-80) 
Moderate impairment (50-60) 
Severe impairment (<50) 
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6) The Time for Mania was assessed in patients which was 
categorized into five groups : 
No episode, 
 <3months,  
3months- 6months,  
6months – 9months,  
9months -12months. 
7) The Time for Depression was assessed which was categorized into 
five groups: 
 No episode, 
<3 months, 
 3months-6months,  
6months- 9months,  
9months-12months. 
8) The number of follow ups was assessed and was categorized into 
five groups: No follow ups,  
One follow up,  
Two follow ups, 
  Three follow ups, 
  Four follow ups. 
19 
 
SAMPLE SIZE:  
            According to the formula to estimate sample size  
   Sample size = (zα+zβ)2*p*q*2 
                                    d
2
 
Estimated sample size is 98 in each group. 
Because of time constrain and availability of patient in our department. 
We thought to have sample size of 52 in each group. 
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RATING SCALES USED: 
YMRS: 
The Young Mania Rating Scale is commonest scale used in mania 
for rating the patients condition over past 48hours.This has 11 items, each 
item has scoring according to the severity of the symptoms. 
Four items are scored from 0-8 and rest seven items are scored from 0-
4
(27,28).
  
HAM-D: 
Hamilton depression rating scale is the commonest scale used in 
depression patients to assess the severity of the illness
 (29 ).
 
          This scale is administered in patients who have no underlying 
organic cause.
(30 )
 
Hamilton 
(31-32 )
reported the scale was not for the diagnostic 
purpose but it was used to differentiate depression from other diagnosis 
like other affective disorders, anxiety disorders and other mental illness 
with varying in there sensitivity and specificity
(33-38 ).
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Modified SADPERSONS scale-to see suicidal score: 
SADS  PERSONS Scale consist of  major 10 factors to assess the risk in 
adult suicide. 
The scoring ranges from 0-14 which consist of age, gender and subjective 
related assessment is done.
(  39)
 
Global assessment of functioning (GAF) scale: 
 
The GAF is translated in many languages and used across the 
world for the assessment of the functioning.
( 40-43)
 
GAF does not reflect the diagnosis of the patient, but needs 
information in many aspects which measures the overall functioning of 
mental illness and psychological condition.
( 43-45)
 
It scores the degree of mental illness by rating the social, 
psychological and occupational functioning.  
( 42-46)
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STATISTICAL ANALYSIS 
The Data entered in excel sheet was conducted using software 
package used for statistical analysis (SPSS) version 20. 
We compared the efficacy of lithium and divalproate sodium  with 
the following variable such as age, gender, marital status and education 
status and were expressed in percentage and their association was 
analysed using chi square test with statistical significance of  P value 
<=0.05. 
The association of age of onset, number of  previous episodes, 
previous hospitalisation, polarity of previous  episodes, psychotrophics 
and duration of  mood stabiliser with that of  lithium and divalproate 
sodium was done using chi-square that with statistical significant of  P 
value <=0.05. 
Association of duration of illness ,association of time for any mood 
episodes, time taken for manic episode, depressive episode ,association of 
severity of  manic episode and depressive episode ,association of suicidal 
risk, adherence to study, association of adverse effects , association of 
global assessment functioning  between lithium and divalproate sodium 
was done using chi-square test with statistical significance of  P value 
<0.05. 
23 
 
We compared the new mood episode with varying serum lithium 
levels, using chi-square test with statistical significant with P value 
<=0.05. 
We   compared the new mood episode with varying divalproate 
dosage, using chi-square test with statistical significant with P value 
<=0.05. 
We compared the frequency with mania and depression episode, 
we depicted in bar diagram. 
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RESULTS 
Table 1:   
Comparison of sociodemographic variable between Lithium and 
Divalproate sodium  group: 
AGE: 
 
 
 
Age 
 Lithium 
Divalproate 
sodium 
P 
value 
Early 
Adulthood 
31(59.6%) 25(48.1%) 
 
 
0.392 
Late 
Adulthood 
18(34.6%) 21(40.4%) 
Geriatric 3(5.8%) 6(11.5%) 
 
31 Patients on lithium had developed bipolar effective disorder in 
early adulthood,18 patients in late adulthood and 3 patients in the 
geriatric group. 
25 patients on divalproate sodium had developed bipolar effective 
disorder in early adulthood, 21 had developed in late adulthood and 6 
developed in geriatric group. 
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GENDER: 
Gender 
 Lithium 
Divalproate 
Sodium 
P Value 
Male 32(61.5%) 39(75.0%) 
0.140 
Female 20(38.5%) 13(25.0%) 
 
32 patients on lithium were male and 20 were female. 
39 patients on divalproate sodium were male and 13 were female. 
EDUCATION STATUS: 
 
 
Education 
Status 
 Lithium 
Divalproate 
sodium 
P value 
Illiterate 7(13.5%) 14(26.9%) 
 
0.101 
Upto 10
th
 
std 
27(51.9%) 20(38.5%) 
11
th
-12
th
 5(9.6%) 10(19.2%) 
Graduate 13(25.0%) 8(15.4%) 
 
Of the patients on lithium, 7 were illiterate, 27 had education until 
10
th
 class, 5 until 12
th
 class and 13 had graduated. In the group of patients 
on divalproate sodium 14 were illiterate, 20 had studied upto 10
th
 class, 
10 upto 12
th
 class and 8 had completed graduation. 
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MARITAL STATUS: 
Marital 
Status 
 Lithium 
Divalproate 
sodium 
P 
value 
Unmarried 15(28.8%) 11(21.2%) 
0.169 
Married, living  
together 
32(61.5%) 26(50.0%) 
Married, living 
separately 
3(5.8%) 7(13.5%) 
Married, 
divorced 
1(1.9%) 4(7.7%) 
Widow/widower 1(1.9%) 4(7.7%) 
 
 
 
Among patients on lithium 15 were unmarried, 32 were married 
and living together, 3 were married and living separately, 1 had divorced 
and 1 was a widow/widower. Among patients receiving divalproate 
sodium 11 were unmarried, 26 were married and living together, 7 were 
married and living separately, 4 were divorced and 4 were 
widow/widower.  
There was no significant difference between the two groups in 
sociodemographic variables like age(P=0.392),Gender(P=0.140), 
Educational qualification(P=0.101) and Marital Status(P=0.169). 
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TABLE 2: 
Impact of confounding variables on Lithium and Divalproate sodium 
patients: 
AGE OF ONSET: 
Age of  
Onset 
 Lithium 
Divalproate 
sodium 
P 
value 
Early 
adulthood 
19(36.5%) 9(17.3%) 
0.085 
Late 
adulthood 
27(51.9%) 36(69.2%) 
Geriatric 6(11.5%) 7(13.5%)  
 
The onset of bipolar disorder among patients on lithium was in 
early adulthood for 19 patients, late adulthood for 27 and old age for 6. 
The onset of bipolar disorder among those receiving divalproate sodium 
was in early adulthood for 9 patients, late adulthood for 36 and old age 
for 7. 
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NUMBER OF EPISODES: 
Number  
of 
Episodes 
 Lithium 
Divalproate 
Sodium 
P 
Value 
1episode 0(0.0%) 3(5.8%) 
0.145 2episode 18(34.6%) 13(25.0%) 
>=3episodes 34(65.4%) 36(69.2%) 
 
Among the patients on lithium 18 patients had 2 episodes and 34 
patients had 3 or more episodes. Among the patients on divalproate 
sodium 3 had 1 episode, 13 had 2 episodes and 36 had 3 or more 
episodes.  
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PREVIOUS HOSPITALISATIONS: 
Previous 
Hospitalisation 
 Lithium 
Divalproate 
sodium 
P 
value 
No hospitalisation 7(13.5%) 6(11.5%) 
 
 
0.594 
1hospitalisation 9(17.3%) 5(9.6%) 
2hospitalisation 15(28.8%) 19(36.5%) 
>=3hospitalisation 20(38.5%) 22(42.3%) 
 
Of the patients receiving lithium, 7 had never been hospitalised for 
the disorder, 9 had been hospitalised once, 15 had been hospitalised twice 
and 20 were hospitalised thrice or more for bipolar disorder. Of the 
patients receiving divalproate sodium, 6 had never been hospitalised for 
the disorder, 5 had been hospitalised once, 19 had been hospitalised twice 
and 22 were hospitalised thrice or more for bipolar disorder. 
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POLARITY OF  PREVIOUS EPISODES: 
Polarity  
of 
previous 
episodes 
 Lithium 
Divalproate 
sodium 
P 
value 
1depressive 
episode 
1(1.9%) 0(0.0%) 
 
 
 
 
0.373 
1manic episode 4(7.7%) 6(11.5%) 
Depression=mania 18(34.6%) 14(26.9%) 
Depression>mania 11(21.2%) 7(13.5%) 
Mania>depression 12(23.1%) 12(23.1%) 
>=2 mania 
episodes 
6(11.5%) 13(25.0%) 
 
Of the patients on lithium, 1 patient had one depressive episode, 4 
had one manic episode, 6 had two or more manic episodes, 18 had 
depression equal to mania, 11 had predominantly depressive episodes and 
12 had predominantly manic episodes. Of the patients on divalproate 
sodium, 6 had one manic episode, 13 had two or more manic episodes, 14 
had depression equal to mania, 7 had predominantly depressive episodes 
and 12 had predominantly manic episodes.  
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PSYCHOTROPHICS: 
 
 
 
 
Psychotrophics 
 Lithium 
Divalproate 
sodium 
P 
value 
No drugs 23(44.5%) 13(25.0%) 
 
 
0.982 
Typical 
antipsychotics 
7(13.5%) 15(28.8%) 
Atypical 
antipsychotics 
19(36.5%) 21(40.4%) 
Antidepressants 2(3.8%) 2(3.8%) 
Benzodiazepines 1(1.9%) 1(1.9%) 
 
Of the patients on lithium, 23 had not taken any drug before, 7 had 
taken typical antipsychotics, 19 had taken atypical antipsychotics, 2 had 
taken antidepressants and 1 had taken benzodiazepines before. Of the 
patients on divalproate sodium, 13 had not taken any drug before, 15had 
taken typical antipsychotics, 21 had taken atypical antipsychotics, 2 had 
taken antidepressants and 1 had taken benzodiazepines before. 
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DURATION OF MOOD STABILIZER: 
Duration of 
Mood 
Stabilizer 
 
 Lithium 
Divalproate 
Sodium 
P value 
<6months 1(1.9%) 0(.0%) 
 
 
 
0.001 
6months-
1year 
7(13.5%) 1(1.9%) 
1-2year 5(9.6%) 20(38.5%) 
>2years 39(75.0%) 31(59.6%) 
 
Among the patients receiving lithium, 1 had taken mood stabilisers 
for less than 6 months,7 had taken for 6-12 months, 5 had taken for 1-2 
years and 39 had taken for more than 2 years. Among the patients 
receiving divalproate sodium, 1 had taken mood stabilisers for 6-12 
months, 20 had taken for 1-2 years and 31 had taken for more than 2 
years. 
There is no statistical significance among the confounding 
variables like Age of onset (P=0.085), Number of episodes (P=0.145), 
Previous hospitalisations (P=0.594), polarity of episodes (P=0.373), 
Psychotrophics (P=0.982) Between the two groups. 
The Duration of illness (P=0.001) was the only confounding 
variable which was significant between the two groups. 
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TABLE NO:3 
Time for any mood episode on patients with Lithium and Divalproate 
sodium: 
3.1TIME FOR MANIA: 
Groups 
TIME  FOR  MANIA 
No 
episode 
<3months 
3-
6months 
6-
9months 
9-12 
months 
P 
Value 
Lithium 
39 
(75.0%) 
5 
(9.6%) 
4 
(7.7%) 
4 
(7.7%) 
0 
(.0%) P=0.3
39 Divalproate 
Sodium 
40 
(76.9%) 
2 
(3.8%) 
3 
(5.8%) 
3 
(5.8%) 
4 
(7.7%) 
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FIGURE NO: 2 
 
 
 
In the lithium group, 39 patients had no episodes of mania, 5 
developed mania in less than 3 months, 4 developed mania between 3 to 6 
months and 4 developed between 6 to 9 months. In the divalproate 
sodium group, 40 patients had no episodes of mania, 2 developed mania 
in less than 3 months, 3 developed mania between 3 to 6 months, 3 
developed between 6 to 9 months and 4 developed between 9 to 12 
months.  
The time taken for manic episode  was not statistically significant 
between Lithium and Divalproate sodium group(P=0.339). 
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3.2  TIME FOR DEPRESSION: 
Groups 
TIME  FOR   DEPRESSION 
P 
VALUE No 
episodes 
<3months 
3-
6months 
6-
9months 
9months-
1year 
Lithium 
 
45 
(86.5%) 
0 
(.0%) 
2 
(3.8%) 
2 
(3.8%) 
3 
(5.8%) 
0.240 
Divalproate 
sodium 
46 
(88.5%) 
1 
(1.9%) 
3 
(5.8%) 
0 
(.0%) 
2 
(3.8%) 
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FIGURE NO:3 
 
In the lithium group, 45 patients had no episodes of depression, 2 
developed depression between 3 to 6 months, 2 developed between 6 to 9 
months and 3 developed between 9 to 12 months.   In the divalproate 
sodium group, 46 patients had no episodes of depression, 1 developed 
depression in less than 3 months, 3 developed depression between 3 to 6 
months and 2 developed between 9 to 12 months.  
The time taken for depressive episode was also not statistically 
significant between Lithium and Divalproate sodium group (P=0.24). 
 
 
 
0
10
20
30
40
50
45
0 2 2 3
46
1 3 0 2
TIME FOR DEPRESSION
LITHIUM
DIVALPROATE 
SODIUM
37 
 
TABLE NO 4: 
Comparision of severity of Manic episode between Lithium and 
Divalproate sodium group: 
YOUNG MANIA RATING SCALE-FOLLOW UP -1: 
Groups 
YOUNG MANIA RATING 
SCALE-FOLLOW UP -1 
 
P  value 
 
No 
Mania 
Mild to 
Modera
te 
Severe 
0.388 Lithium 
47 
(90.4%) 
1 
(1.9%) 
4 
(7.7%) 
Divalproate 
sodium 
 
50 
(96.2%) 
1 
(1.9%) 
1 
(1.9%) 
 
Among patients on lithium, 47 had no mania, 1 had mild to 
moderate mania and 4 had severe mania according to Young  Mania 
Rating Scale, on the first follow up. Among patients on divalproate 
sodium, 50 had no mania, 1 had mild to moderate mania and 1 had severe 
mania. 
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YOUNG  MANIA  RATING  SCALE-FOLLOW UP -2: 
Groups 
YOUNG MANIA RATING 
SCALE-FOLLOW UP -2 
 
P  value 
 
 
No Mania 
Mild to 
Moderate 
Severe 
 
 
 
 
0.696 
Lithium 
48 
(92.3%) 
0 
(.0%) 
4 
(7.7%) 
Divalproate 
sodium 
 
49 
(94.2%) 
0 
(.0%) 
 
3 
(5.8%) 
 
Among patients on lithium, 48 had no mania and 4 had severe 
mania according to Young Mania Rating Scale, on the second follow up. 
Among patients on divalproate sodium, 49 had no mania and 3 had severe 
mania. 
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YOUNG  MANIA  RATING SCALE-FOLLOW UP -3: 
Groups 
YOUNG MANIA RATING 
SCALE-FOLLOW UP -3 
 
P  value 
 
 
No 
Mania 
Mild to 
Moderate 
Severe 
0.331 Lithium 
48 
(92.3%) 
2 
(3.8%) 
2 
(3.8%) 
Divalproate 
sodium 
49 
(94.2%) 
0 
(.0%) 
3 
(5.8%) 
 
Among patients on lithium, 48 had no mania, 2 had mild to 
moderate mania and 2 had severe mania according to Young Mania 
Rating Scale, on the third follow up. Among patients on divalproate 
sodium, 49 had no mania and 3 had severe mania. 
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YOUNG  MANIA  RATING  SCALE-FOLLOW UP -4: 
 
Groups 
YOUNG MANIA RATING 
SCALE-FOLLOW UP -4 
 
P  
value 
 
 
No 
Mania 
Mild to 
Moderate 
Severe  
 
 
 
0.041 
Lithium 
52 
(100.0%) 
0 
(.0%) 
0 
(.0%) 
Divalproate 
sodium 
48 
(92.3%) 
0 
(.0%) 
4 
(7.7%) 
 
 
Among patients on lithium, 52 had no mania according to Young 
Mania Rating Scale, on the fourth follow up. Among patients on 
divalproate sodium, 48 had no mania and 4 had severe mania. 
Patients who are taking Divalproate sodium had more severe 
Manic episode at the end of 1 year (4patients v/s none – P=0.041) ,but 
was not significant during initial three follow ups (P=0.388,0.696,0.331). 
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TABLE NO 5: 
Comparision of  severity of  depressive  episode  between Lithium 
and Divalproate sodium group: 
HAMILTON DEPRESSION RATING SCALE – FOLLOW UP- 1: 
 
Groups 
 
HAMILTON DEPRESSION RATING 
SCALE – FOLLOW UP- 1 
P Value 
No 
depression 
Mild -
Moderate 
Severe 
Lithium 
52 
(100.0%) 
0 
(.0%) 
0 
(.0%) 
 0.315 
Divalproate 
sodium 
51 
(98.1%) 
1 
(1.9%) 
0 
(.0%) 
 
Among patients on lithium,52 had no depression according to 
Hamilton Depression Rating Scale, on the first follow up. Among patients 
on divalproate sodium, 51 had no depression and 1 had mild to moderate 
depression. 
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HAMILTON DEPRESSION RATING SCALE – FOLLOW UP- 2: 
Groups 
HAMILTON DEPRESSION RATING 
SCALE – FOLLOW UP- 2 P 
Value No 
depression 
Mild -
Moderate 
Severe 
Lithium 
50 
(96.2%) 
1 
(1.9%) 
1 
(1.9%) 
0.842 
Divalproate 
sodium 
49 
(94.2%) 
1 
(1.9%) 
2 
(3.8%) 
 
Among patients on lithium, 50 had no depression, 1 had mild to 
moderate depression and 1 had severe depression according to Hamilton 
Depression Rating Scale, on the second follow up. Among patients on 
divalproate sodium, 49 had no depression, 1 had mild to moderate 
depression and 2 had severe depression. 
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HAMILTON DEPRESSION RATING SCALE – FOLLOW UP- 3: 
 
 
Groups 
 
HAMILTON DEPRESSION RATING 
SCALE – FOLLOW UP- 3 
P Value 
No 
depression 
Mild -
Moderate 
Severe 
Lithium 
50 
(96.2%) 
0 
(.0%) 
2 
(3.8%) 
0.153 
Divalproate 
sodium 
52 
(100.0%) 
0 
(.0%) 
0 
(.0%) 
 
Among patients on lithium, 50 had no depression and 2 had severe 
depression according to Hamilton Depression Rating Scale, on the third 
follow up. Among patients on divalproate sodium, 52 had no depression. 
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HAMILTON DEPRESSION RATING SCALE – FOLLOW UP- 4: 
 
Groups 
HAMILTON DEPRESSION 
RATING SCALE – FOLLOW UP- 4 
P Value 
No 
depression 
Mild -
Moderate 
Severe 
Lithium 
49 
(94.2%) 
0 
(.0%) 
3 
(5.8%) 
0.366 
Divalproat
e sodium 
50 
(96.2%) 
1 
(1.9%) 
1 
(1.9%) 
 
Among patients on lithium, 49 had no depression and 3 had severe 
depression according to Hamilton Depression Rating Scale, on the fourth 
follow up. 
Among patients on divalproate sodium, 50 had no depression, 1 
had mild to moderate depression and had severe depression. 
There was no difference in the severity of depressive episode 
during all four follow ups upto one year between Lithium and 
Divalproate sodium patients. 
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TABLE NO:6 
To Evaluate for Suicidal risk between Lithium and Divalproate 
sodium group: 
SUICIDAL RISK SCALE BASELINE: 
 SUICIDAL RISK SCALE BASELINE 
Groups 
 
No risk 
Moderate 
risk 
Severe 
risk 
P Value 
Lithium 
37 
(71.2%) 
15 
(28.8%) 
0 
(.0%) 
 
 
0.671 
Divalproate 
sodium 
35 
(67.3%) 
17 
(32.7%) 
0 
(.0%) 
 
Among patients on lithium, 37 had no suicidal risk, 15 had 
moderate risk according to suicidal risk scale. Among patients on 
divalproate sodium, 35 had no suicidal risk, 17 had moderate risk and 3 
had severe risk. 
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SUICIDAL RISK SCALE FOLLOW UP-1: 
 
 SUICIDAL RISK SCALE FOLLOW UP:1 
Groups No risk 
Moderate 
risk 
Severe 
risk 
P Value 
Lithium 
35 
(67.3%) 
14 
(26.9%) 
3 
(5.8%) 
 
 
0.173 
Divalproate 
sodium 
34 
(65.4%) 
18 
(34.6%) 
0 
(.0%) 
 
Among patients on lithium, 35 had no suicidal risk, 14 had  
moderate risk and 3 had severe risk  according to suicidal risk scale, on 
the first follow up. Among patients on divalproate sodium, 34 had no 
suicidal risk, 18 had moderate risk . 
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SUICIDAL RISK SCALE FOLLOW UP-2: 
 SUICIDAL RISK SCALE FOLLOW UP:2 
Groups No risk 
Moderate 
risk 
Severe 
risk 
P Value 
Lithium 
39 
(67.3%) 
9 
(26.9%) 
4 
(7.7%) 
0.371 
Divalproate 
sodium 
34 
(65.4%) 
15 
(28.8%) 
3 
(5.8%) 
 
Among patients on lithium, 39 had no suicidal risk, 9 had  
moderate risk and 4 had severe risk  according to suicidal risk scale, on 
the second follow up. Among patients on divalproate sodium, 34 had no 
suicidal risk, 15 had moderate risk.  
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SUICIDAL RISK SCALE FOLLOW UP-3: 
 SUICIDAL RISK SCALE FOLLOW UP:3 
Groups No risk 
Moderate 
risk 
Severe 
risk 
P Value 
Lithium 
42 
(80.8%) 
8 
(15.4%) 
2 
(3.8%) 
 
 
0.857 
Divalproate 
sodium 
40 
(76.9%) 
9 
(17.3%) 
3 
(5.8%) 
 
Among patients on lithium, 42  had no suicidal risk, 8 had  
moderate risk and 2 had severe risk  according to suicidal risk scale, on 
the third follow up. Among patients on divalproate sodium, 40 had no 
suicidal risk, 9 had moderate risk and 3 had severe risk. 
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SUICIDAL RISK SCALE FOLLOW UP-4: 
 SUICIDAL RISK SCALE FOLLOW UP:4 
Groups No risk 
Moderate 
risk 
Severe risk P Value 
Lithium 
47 
(90.4%) 
3 
(5.8%) 
2 
(3.8%) 
0.073 
Divalproate 
sodium 
38 
(73.1%) 
9 
(17.3%) 
5 
(9.6%) 
 
Among patients on lithium, 47 had no suicidal risk, 3 had moderate 
risk and 2 had severe risk according to suicidal risk scale, on the fourth 
follow up. Among patients on divalproate sodium, 38 had no suicidal 
risk, 9 had moderate risk and 5 had severe risk. 
The severity of suicidal scale was not significant during initial and 
all four follow-ups,but was trending towards significance during the 12
th
 
month follow up(P=0.671,0.173,0.371,0.857,0.073). 
 
 
 
 
 
 
50 
 
TABLE NO:7 
Adherence to study treatment: 
Groups 
NUMBER OF FOLLOW UPS 
P 
value 
No 
follow 
ups 
1 
follow 
up 
2follow 
up 
3follow 
up 
4follow 
up 
Lithium 
4 
(7.7%) 
5 
(9.6%) 
8 
(15.4%) 
10 
(19.2%) 
25 
(48.1%) 
0.938 
Divalproate 
sodium 
5 
(9.6%) 
4 
(7.7%) 
8 
(15.4%) 
13 
(25.0%) 
22 
(42.3%) 
 
 
Among 52 Lithium group patients,25 patients (48.1%) had 
completed all four follow ups as compared to 22 divalproate sodium goup 
patients (42.3%). 
But the above findings were not statistically significant(P=0.938). 
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TABLE  NO:8 
Adverse effects of the treatment: 
ADVERSE DRUG REACTION BASELINE: 
ADVERSE DRUG REACTION BASELINE 
Groups 
 
No drug 
reaction 
Minimal 
reaction 
More 
reactio
n 
P Value 
Lithium 
28 
(53.8%) 
24 
(46.2%) 
0 
(.0%) 
0.303 
Divalproa
te sodium 
24 
(46.2%) 
26 
(50.0%) 
2 
(3.8%) 
 
Among patients on lithium, 28 had no adverse drug reaction and 24 
had mild <3 reactions at baseline. Among patients on divalproate sodium, 
24 had no reactions, 26 had <3 reactions and 2 had >=3 reactions. 
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ADVERSE DRUG REACTION FOLLOW UP-1: 
ADVERSE DRUG REACTION FOLLOW UP-1 
Groups 
No drug 
reaction 
Minimal 
reaction 
More 
reaction 
P Value 
Lithium 
23 
(44.2%) 
29 
(55.8%) 
0 
(.0%) 
0.057 
Divalproate 
sodium 
24 
(46.2%) 
23 
(44.2%) 
5 
(9.6%) 
 
Among patients on lithium, 23 had no adverse drug reaction and 29 
had <3 reactions on first follow up. Among patients on divalproate 
sodium, 24 had no reactions, 23 had <3 reactions and 5 had >=3 
reactions. 
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ADVERSE DRUG REACTION FOLLOW UP-2: 
ADVERSE DRUG REACTION FOLLOW UP-2 
Groups   
No drug 
reaction 
Minim
al 
reactio
n 
More 
reaction 
P Value 
Lithium 
27 
(51.9%) 
25 
(48.1%) 
0 
(.0%) 
0.361 
Divalproa
te sodium 
26 
(50.0%) 
24 
(46.2%) 
2 
(3.8%) 
 
Among patients on lithium, 27 had no adverse drug reaction and 25 
had <3 reactions on second follow up. Among patients on divalproate 
sodium, 26 had no reactions, 24 had <3 reactions and 2 had >=3 
reactions. 
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ADVERSE DRUG REACTION FOLLOW UP-3: 
ADVERSE DRUG REACTION FOLLOW UP-3 
Groups 
No drug 
reaction 
Minimal 
reaction 
More 
reaction 
P Value 
Lithium 
30 
(57.7%) 
22 
(42.3%) 
0 
(.0%) 
0.312 
Divalproate 
sodium 
35 
(67.3%) 
16 
(30.8%) 
1 
(1.9%) 
 
Among patients on lithium, 30 had no adverse drug reaction and 22 
had <3 reactions on third follow up. Among patients on divalproate 
sodium, 35 had no reactions, 16 had <3 reactions and 1 had >=3 
reactions. 
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ADVERSE DRUG REACTION FOLLOW UP-4: 
ADVERSE DRUG REACTION FOLLOW UP-4 
Groups 
No drug 
reaction 
Minimal 
reaction 
More 
reaction 
P Value 
Lithium 
42 
(80.8%) 
10 
(19.2%) 
0 
(.0%) 
0.340 
Divalproate 
sodium 
39 
(75.0%) 
11 
(21.2%) 
2 
(3.8%) 
 
Among patients on lithium, 42 had no adverse drug reaction and 10 
had <3 reactions on fourth follow up. Among patients on divalproate 
sodium, 39 had no reactions, 11 had <3 reactions and 2 had >=3 
reactions. 
The adverse drug effect (catagorised as nausea, diarrhea, 
tremors,weight gain, sedation, polydipsia, polyuria, tachycardia, alopecia, 
any major skin lesions , hypothyroid symptoms, signs of renal 
dysfunction) profile was the same between Lithium and Divalproate 
sodium group during all four visits except during initial follow 
up(3months) in which Lithium group was better than Divalproate sodium 
group (five patients on Divalproate sodium group had >=3 adverse drug 
reaction compared to none in the Lithium group). 
The above result was not statistically significant. 
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TABLE NO:9 
Global Assessment Functioning : 
GLOBAL ASSESSMENT FUNCTIONING  - BASELINE: 
 
Groups 
 
 
Global Assessment Functioning – 
BASELINE 
P 
Valu
e 
Good 
Mild 
impairmen
t in 
functioning 
Moderate 
impairmen
t in 
functioning 
Severe 
impairmen
t 
0.315 
Lithium 
51 
(98.1%) 
1 
(1.9%) 
0 
(.0%) 
0 
(.0%) 
Divalproat
e sodium 
52 
(100.0%
) 
0 
(.0%) 
0 
(.0%) 
0 
(.0%) 
 
Global assessment functioning among patients on lithium was good 
in 51 and mildly impaired in 1 at baseline. Among patients on divalproate 
sodium, all 52 patients had good functioning. 
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GLOBAL ASSESSMENT FUNCTIONING  FOLLOW UP-1: 
Global assessment functioning follow up-1 
P 
Valu
e 
Groups Good 
Mild 
impairme
nt in 
functionin
g 
Moderate 
impairme
nt in 
functionin
g 
Severe 
impairme
nt 
 
 
 
 
 
0.553 
Lithium 
 
46 
(88.5%
) 
2 
(3.8%) 
3 
(5.8%) 
1 
(1.9%) 
Divalproat
e sodium 
49 
(94.2%
) 
2 
(3.8%) 
1 
(1.9%) 
0 
(.0%) 
 
Global assessment functioning among patients on lithium was good 
in 46, mildly impaired in 2, moderately impaired in 3 and severely 
impaired in 1 patient, on first follow up. Among patients on divalproate 
sodium, 49 had good functioning, 2 had mild impairment and 1 had 
moderate impairment. 
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GLOBAL ASSESSMENT  FUNCTIONING  FOLLOW UP-2: 
 Global assessment functioning follow up-2 
P 
Value 
Groups Good 
Mild 
impairment 
in 
functioning 
Moderate 
impairment 
in 
functioning 
Severe 
impairment 
 
 
 
 
 
0.912 
Lithium 
46 
(88.5%) 
1 
(1.9%) 
3 
(5.8%) 
2 
(3.8%) 
Divalproate 
sodium 
46 
(88.5%) 
2 
(3.8%) 
2 
(3.8%) 
2 
(3.8%) 
 
Global assessment functioning among patients on lithium was good 
in 46, mildly impaired in 1, moderately impaired in 3 and severely 
impaired in 2 patients, on second follow up. Among patients on 
divalproate sodium, 46 had good functioning, 2 had mild impairment, 2 
had moderate impairment and 2 had severe impairment. 
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GLOBAL ASSESSMENT FUNCTIONING  FOLLOW UP-3: 
 Global assessment functioning follow up-3 
P 
Value 
Groups Good 
Mild 
impairment 
in 
functioning 
Moderate 
impairment 
in 
functioning 
Severe 
impairment 
 
 
 
 
 
0.330 
Lithium 
 
46 
(88.5%) 
2 
(3.8%) 
3 
(5.8%) 
1 
(1.9%) 
Divalproate 
sodium 
49 
(94.2%) 
0 
(.0%) 
1 
(1.9%) 
2 
(3.8%) 
 
Global assessment functioning among patients on lithium was good 
in 46, mildly impaired in 2, moderately impaired in 3 and severely 
impaired in 1 patients, on third follow up. Among patients on divalproate 
sodium, 49 had good functioning, 1 had moderate impairment and 2 had 
severe impairment. 
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GLOBAL ASSESSMENT FUNCTIONING  FOLLOW UP-4: 
Global assessment functioning follow up-4 P value 
Groups Good 
Mild 
impairment 
in 
functioning 
Moderate 
impairment 
in 
functioning 
Severe 
impairment 
0.117 
Lithium 
 
49 
(94.2%) 
0 
(.0%) 
3 
(5.8%) 
0 
(.0%) 
Divalproate 
sodium 
46 
(88.5%) 
0 
(.0%) 
2 
(3.8%) 
4 
(7.7%) 
 
Global assessment functioning among patients on lithium was good 
in 49 and moderately impaired in 3patients on fourth follow up. Among 
patients on divalproate sodium, 46 had good functioning, 2 had moderate 
impairment and 4 had severe impairment. 
During the initial follow ups Lithium group patients had more 
functional impairment than Divalproate sodium group patients(initial and 
3
rd
 follow up). 
  During 6
th
 month follow up two patients in each group had severe 
impairment.During 9
th
 month and 1year follow up,Divalproate sodium  
group had more severe functional impairment than Lithium group(1 v/s 2 
),(0 v/s 4) but was not statistically significant. 
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TABLE NO:10 
Comparision of new mood episode with varying serum lithium level: 
Serum lithium 
level 
New onset 
mania 
New  onset 
depression 
<0.8 6 4 
0.8-1.2 5 3 
>1.2 2 1 
 
We also calculated the patients who developed a new 
manic/depressive episode with varying serum lithium level. 
Six out of thirteen new episode manic patients had a lower serum 
lithium level likewise majority of new onset depression episode patient 
(four out of eight), had a lower serum lithium level. 
  
 
 
 
 
 
 
62 
 
TABLE NO:11 
Comparision of new mood episode with varying dosage of 
divalproate sodium:  
Dosage of divalproate 
sodium 
New 
onset 
mania 
New onset 
depression 
<1gm 1 1 
1gm-1.5gm 8 5 
>1.5gm 3 0 
 
Among the divalproate sodium group patients, only three out of 
thirteen patients who were on adequate dose (more than 1.5gm), has new 
onset mania (nine out of twelve patients were on inadequate dose). 
None of the divalproate sodium group patients had new onset 
mania who are on adequate dose (all six patients who had new onset 
depression were on subtherapeutic dose). 
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FIGURE NO:4 
Comparision of  Frequency  of  Manic and Depressive episode 
between two groups: 
 
 
Among Lithium group patients 13had Manic episode and 8 had 
Depressive episode. Among Divalproate sodium group patients 12 had 
Manic episode and 6 had Depressive episode. 
In both the groups Manic episode was more common than 
Depressive episode. 
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DISCUSSION 
We did a prospective study , comparing the mood stabilising effect 
of lithium and  divalporate sodium in euthymic bipolar patients. Our 
study was an one year periodic prospective study done in psychiatry 
department at a teritiary hospital. 
When we compared the sociodemographic variables (age, gender, 
educational status ,marital status)there was no statistical significance 
between the two groups. 
We also considered the confounding variables namely (age of 
onset, number of previous episodes, previous hospitalisation, polarity of 
previous episodes and use of psychotrophics) ,which  was also not 
significant between the two groups. 
But the duration of mood stabiliser,(lithium group patients had 
more duration of treatment than  divalproate sodium group patients),was 
statistically significant between the two groups. 
The serum lithium level was less than adequate in majority of new 
onset manic/depressive episode patients. 
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Majority of the patients who developed new onset 
manic/depressive episode were on subtherapeutic dose of divalproate 
sodium. 
PRIMARY OUTCOME: 
Comparision of  Frequency  of  Manic and Depressive episode 
between  two groups: 
In both lithium and divalproate sodium groups, similar number of 
patients had   manic episode(13 v/s 12) and depressive (8 v/s 6). 
The predominant mood episode was mania in both the groups. The 
above finding could also be because the polarity of previous 
episode in both the groups was predominantly mania. 
B) Time for manic episode on patients with lithium and 
divalproate sodium: 
Bipolar  patients on lithium therapy had more manic episodes until 
first 9months of follow up but during the 1
st
 year follow up, 
divalproate sodium had more manic episodes. 
The above finding emphasises lithium to be a better long term 
mood stabiliser than divalproate sodium.  
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C) Time for depressive episode on patients with lithium and    
          divalproate  sodium: 
There was no statistical difference between the lithium and 
divalproate sodium group, although lithium patient had more 
depressive episode than divalproate sodium patients. 
SECONDARY OUTCOME: 
A) The severity of mood episode in lithium and divalproate 
        groups: 
 The patient who were on divalproate arm, had more severe manic 
 episode, as the duration of  follow up increased. This again 
emphasises  lithium ,being a better antimanic agent ever during 
long term follow up.   
 The severity of depressive episodes did not differ between both the 
 groups. 
B) Comparision of suicidal risk between lithium and divalproate  
          sodium patients: 
Bipolar patients who were on lithium had lower suicidal risk than 
divalproate patients, especially on prolonged duration of 
treatment(during 1
st
 year follow up trending towards significance). 
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Hence we believe if  lithium group patients were had  followed up 
for longer duration would had less new onset depressive episodes. 
C) Adherence to study treatment: 
Both lithium and divalproate sodium group patients had almost 
equal follow ups and hence were equally adherent to treatment. 
Two patients on lithium were changed to divalproate sodium as 
they had severe skin reaction which affected the study adherence. 
D) Adverse effects of medication: 
Adverse effect profile did not differ during initial and periodic 
assessment between the two groups . 
Bipolar patients on divalproate sodium had more adverse effects 
during initial follow ups, which was not seen during further follow 
up. 
E) Global assessment of functioning: 
The global functioning was better in lithium group , but was not 
statistically significant. 
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LIMITATIONS 
1. Sample size was small and hence the results cannot  be generalised. 
2. Telephonic assessments for patients who missed follow ups, cannot 
be as reliable as face to face interview. 
3. Our sample was convenient sample, a computer generated 
sampling would have been better. 
4. Use of other psychotrophics  (antipsychotics, benzodiazepines) 
were allowed. We  know medication like olanzapine, risperidone 
and quetiapine can have a mood stabilising effect.
(17,18,20
 
5. Among lithium group patients, only two patients were changed to 
divalproate sodium in view of cutaneous side effects, which could 
have affected the adherence between the two groups. 
6. We followed the patient, only  upto 1year , which is a short 
duration considering the chronicity of mood disorder. 
7. In our study, bipolar patients on lithium were better than 
divalproate sodium in preventing the manic episode which needs a 
longer follow up study. 
8. Adherence of both the group patients were equated to the number 
of follow ups. Instead pill count could have been a better marker. 
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9. The categorisation of the dosage of divalproate sodium was 
arbitrary. 
10. The severity of adverse drug effects were assessed only based on 
number of adverse effects than categorizing into simple and serious 
adverse effects. 
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CONCLUSION 
1) The frequency of manic episode was better in lithium group of 
patients as the duration  of lithium therapy increased. 
2) The frequency of depressive episode was similar between the 
lithium and divalproate sodium groups. 
3) The severity of manic episode was lesser in lithium group of 
patients, when treated for a longer duration. 
4) Suicidal risk was lesser in lithium group patients. 
5) In terms of adherence , adverse effects profile and global 
functioning both the groups did not differ. 
6) Lithium continues to be a gold standard inspite of seven decades of 
dominance as a mood stabilizer agent. 
7) Our study emphasis the need to treat the bipolar patients with 
adequate dosage. 
 
 
 
 
 
71 
 
REFRENCES 
1. Murray CJL, Lopez AD. Global mortality, disability, and the 
contribution of risk factors: Global Burden of Disease Study. 
Lancet 1997; 349: 1436–42. 
2. American Psychiatric Association. Practice guideline for the 
treatment of patients with   bipolar disorder (revision).Am J 
Psychiatry 2002; 159 (4 suppl): 1–50. 
3. Goodwin GM. Evidence-based guidelines for treating bipolar 
disorder: revised second edition—recommendations from the 
British Association for Psychopharmacology. J 
Psychopharmacol2009; 23: 346–88. 
4. National Institute for Health and Clinical Excellence. Bipolar 
disorder: the management of bipolar disorder in adults, children 
and adolescents, in primary and secondary care. 
http://guidance.nice.org.uk/CG38 (accessed Nov 19, 2009). 
5. Geddes JR, Burgess S, Hawton K, Jamison K, Goodwin GM. 
Longterm lithium therapy for bipolar disorder: systematic review 
and meta-analysis of randomized controlled trials. Am J 
Psychiatry 2004; 161: 217–22. 
72 
 
6. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the 
prevention of suicidal behaviour and all-cause mortality in 
patients with mood disorders: a systematic  review  of 
randomised trials.Am J Psychiatry 2005; 162: 1805–19. 
7.  Soares-Weiser K, Bravo Vergel Y, Beynon S, et al. A systematic 
review and economic   model of the clinical effectiveness and 
cost effectiveness of interventions for preventing  relapse in 
people withectiveness of interventions for preventing relapse in 
people with bipolar disorder. Health Technol Assess 2007; 11: 1–
226. 
8. Coryell W,Winokur G,SolomonD,sheaT,leonA,kellerM.lithium 
and recurrence in long term follow up of bipolar affective 
disorder.psychol med.1997;27:281-289. 
9. Chan HH, Wing Y, and Su R. et al. A control study of the 
cutaneous side effects of chronic lithium therapy. J Affect Disord. 
2000 57:107–113. 
10. Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, 
Petty F, Dil-saver SC, Davis JM, Rush AJ, Small JG, Garza-
Trevino ES, Risch SC, GoodnickPJ, Morris DD, for the 
73 
 
Depakoke Mania Study Group. Efficacy of divalproex vs lithium 
and lacebo in the treatment of mania. JAMA. 1994;271:918-924. 
11. Pope HG Jr, McElroy SL, Keck PE Jr, Hudson JI. Valproate in 
the treatment o acute mania: a placebo-controlled study. Arch 
Gen Psychiatry. 1991;48:62-68.   
12. John R Geddes (chief investigator), Guy M Goodwin,Jennifer 
Rendell (trial manager), Jean-Michel Azorin (chief 
investigator,France), Andrea Cipriani (chief investigator, Verona, 
Italy), and et.al , Lithium plus valproate combination therapy 
versus monotherapy for relapse prevention in bipolar I 
disorder(BALANCE): a randomised open-label trial Lancet 2010 
: 375:385-395. 
13. A Randomized, Placebo-Controlled 12-Month Trial of 
Divalproex and Lithium in Treatment of Outpatients With 
Bipolar I Disorder Charles L. Bowden, MD; Joseph R. Calabrese, 
MD; Susan L. McElroy, MD; Laszlo Gyulai, MD; Adel Wassef, 
MD; Frederick Petty, MD, PhD; Harrison G. Pope, Jr, MD; 
James C.-Y. Chou, MD; Paul E. Keck, Jr, MD;Linda J. Rhodes, 
MD; Alan C. Swann, MD; Robert MA. Hirschfeld, MD; Patricia 
74 
 
J. Wozniak, PhD;for Divalproex  Maintenance Study Group Arch 
Gen Psychiatry. 2000;57:481-489. 
14. Lambert PA, Venaud G. Comparative study of valpromide versus 
lithium in the treatment of affective disorders. Nervure. 
1992;5:57 
15. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 
55 patients with rapid-cycling bipolar disorder. AM J Psychiatry, 
1990;147:431-434  
16. McElroy SL, Keck PE Jr. Pope HG Jr. Sodium Valproate :its use 
in primary psychiatric disorders. J.clin Psychopharmacol. 
1987;7;16-24. 
17. Bowden CL, Ketter TA, Sachs GS, Thase ME. Focus on bipolar 
disorder treatment. J. Clin. Psychiatry.2005b;66:1598–1609. 
18. FDA FDA approved drug products. 2009.  
19. Fountoulakis KN, Grunze H, Panagiotidis P, Kaprinis G. 
Treatment of bipolar depression: an update. J Affect 
Disord. 2008;109:21–34. 
75 
 
20. Ketter TA, Wang PW, Nowakowska C, editors. Treatment of 
acute mania in bipolar disorder. American Psychiatric Publishing; 
Washington, DC: 2005. 
21. Bowden CL. Acute and maintenance treatment with mood 
stabilizers. Int J Neuropsychopharmacol.2003;6:269–75. 
22. Bowden CL. Predictors of response to divalproex and lithium. J 
Clin Psychiatry. 1995;56(Suppl 3):25–30. 
23. Swann AC, Bowden CL, Morris D, Calabrese JR, Petty F, Small 
J, Dilsaver SC, Davis JM. Depression during mania. Treatment 
response to lithium or divalproex. Arch Gen 
Psychiatry. 1997;54:37–42. 
24. Kleindienst N, Greil W. Differential efficacy of lithium and 
carbamazepine in the prophylaxis of bipolar disorder: results of 
the MAP  study.  Neuropsychobiology . 2000;42(Suppl 1):2–10. 
25. Lerer B, Moore N, Meyendorff E, Cho SR, Gershon S. 
Carbamazepine versus lithium in mania: a double-blind 
study. JClin Psychiatry. 1987;48:89–93.  
26. Vasudev K, Goswami U, Kohli K. Carbamazepine and valproate 
monotherapy: feasibility, relative safety and efficacy, and 
76 
 
therapeutic drug monitoring in manic 
disorder. Psychopharmacology (Berl) 2000;150:15–23. 
27. Young RC, Biggs JT, Ziegler VE, Meyer DA, A rating scale for 
mania reliability, validity and sensitivity.  Br.J Psychiatry. 
1978;133;429-435 
28. Young RC, Biggs JT, Ziegler VE, Meyer DA. Young mania 
rating scale in hand book of psychiatric measures Washington 
DC; American Psychiatry Association, 2000:542 -545. 
29. Hamilton M. A rating scale for depression; J.Neurol nerosurg 
psychiatry. 1960 Feb;23: 56-62 
30. Leentjens AF, Verhey FR, Lousberg R, Spitsbergen, H, Wilmink 
FW. The validity of the Hamilton and Montgomery Asberg 
depression rating scales as screening and diagnostic  tools for 
depression in Parkinson’s disease. Int. J.Geriatr Psychiatry. 2000 
Jul;15(7):644 – 649 
31. Hamilton M(1960).A rating scale for depression. journal of 
neurology, neurosurgery and psychiatry.23,56-62. 
77 
 
32. Hamilton M(1967). Development of a rating scale for primary 
depressive illness. British journal of social and clinical 
psychiatry.6,278-296 
33. Kobak,K.A. ,Reynolds, W.R,.Rosenfeld.R., & Greist,J.H. (1990). 
Development and validation of a computer administrated 
Hamilton derpression rating scale.psychological assessment.2,56-
63. 
34. Maier,W,Philippe.M.Heuser.I.Schlegel.S.Buller.R.&Wetze.H(19
88).Improving depression severity assessment-1.Reliability , 
internal validity and sensitivity to change of three observer 
depression scales.journal of psychiatric research 22.3-12 
35. Rehm,L.P.,&O’Hora ,M.W(1985). Item characteristics of the 
Hamilton rating scale of depression. journal of psychiatry 
research,19.31-41. 
36. Reynolds,W.M., & Kobak ,K.A(1995a). Development and 
validation of the Hamilton Depression inventory:A self report 
version of the Hamilton Depression rating scale. Psychological 
assessment 7,472-483. 
37. Riskind,J.H.,Beck,A.T.,Brown,G.,& Steer ,R.A,(1987).Taking 
the measure of anxiety and depression: validity of the 
78 
 
reconstructed Hamilton scales.journal of Nervous and mental 
disease.175,474-479. 
38. Thase,M.E., Hersen, M., BellackA.S., Himmelhoch,J.M.,& 
Kupfer,D.J. (1983).Validation of a Hamilton subscale for 
endogenomorphic depression. Journal of affective 
disorders,5,267-278. 
39. Patterson WM, Dohn HH, Bird J, Patterson GA: Evaluation of 
suicidal patients: the   SAD PERSONS score. Psychosomatics 
24:343–349, 1983. 
40. Piersma HL, Boes JL. The GAF and psychiatric outcome: a 
descriptive report. Comm Ment Health J.1997; 33:35–41. doi: 
10.1023/ A:1022413110345.  
41. Salvi G, Leese M, Slade M. Routine use of mental health 
outcome assessments: choosing the measure. Br J 
Psychiatry. 2005;186:146–152.  
42. Vatnaland T, Vatnaland J, Friis S, Opjordsmoen S. Are GAF 
scores reliable in routine clinical use?Acta Psychiatr 
Scand. 2007;115:326–330.  
79 
 
43. Schorre BEH, Vandvik IH. Global assessment of psychosocial 
functioning in child and adolescent psychiatry. A review of three 
unidimensional scales (CGAS, GAF, GAPD) Eur Child Adolesc 
Psychiatry. 2004;13:273–286.  
44. Moos RH, McCoy L, Moos BS. Global Assessment of 
Functioning (GAF) ratings: determinants and role as predictors of 
one-year treatment outcomes. J Clin Psychol. 2000;56:449–461.  
45. Rosse RB, Deutsch SI. Use of the Global Assessment of 
Functioning scale in the VHA: moving toward improved 
precision. Veterans Health Syst J. 2000;5:50–58. 
46. Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-
IV: a review of measures of social functioning. Am J 
Psychiatry. 1992;149:1148–1156. 
47. Martin A lda et al ,‖Lithium in the treatment of Bipolar Disorder : 
Pharmacology and Pharmacogenetics ―  Mol Psychiatry. 2015 
June ; 20(6): 661–670. 
48. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC 
(1992). A double-blind comparison of valproate and lithium in 
the treatment of acute mania. Am J Psychiatry 149: 108–111. 
80 
 
49. Himmelhoch JM, Garfinkel ME (1986). Sources of lithium 
resistance in mixed mania. Psychopharmacol Bull 22 : 613–620. 
50. Keller MB, Lavori PW, Coryell W, Andreasen NC, Endicott J, 
Clayton PJ et al (1986).  Differential outcome of pure manic, 
mixed/cycling, and pure depressive episodes in patients with 
bipolar illness. JAMA :255 : 3138–3142. 
51. Keller MB (1988). The course of manic-depressive illness. J Clin 
Psychiatry:49 (Suppl): 4–7. 
52. Secunda S, Katz MM, Swann AC, Koslow SH, Maas JW, Chang 
S et al (1985). Mania: diagnosis, state measurement, and 
prediction of treatment response. J Affect Disorder :8: 113–121 
53. Secunda S, Swann AC, Katz MM, Koslow SH, Croughan J, 
Chang S (1987). Diagnosis and  treatment of mixed mania. Am J 
Psychiatry :144 : 96–98. 
54. Swann AC, Bowden CL, Calabrese JR, Dilsaver SC, Morris DD 
(1999). Differential effect of number of previous episodes of 
affective disorder on response to lithium or divalproex in acute 
mania. Am J Psychiatry:156: 1264–1266. 
 
81 
 
ANNEXURES 
INFORMED  CONSENT  (ENGLISH) 
PSG Institute of Medical Science and Research, Coimbatore 
Institutional Human Ethics Committee 
INFORMED CONSENT FORMAT FOR RESEARCH PROJECTS 
 
(strike off items that are not applicable) 
 
I, Dr Sarah Afreen am carrying out a study on the topic: Effectiveness of 
mood stabilizer in euthymic BPAD patients-an one year 
prospective observational study, comparing  LITHIUM V/S  
DIVALPROATE SODIUM. In DEPARTMENT OF 
PSYCHIATRY OP patients.  
(Applicable to students only): My / our research guide is: Dr.  SYED 
UMMAR .I. 
The justification for this study is: To study the effectiveness of mood 
stabilizer in euthyic BPAD patients. 
 
The objectives of this study are:  
 
Primary Objective: To evaluate the time for any mood episode (mania/ 
depression/ mixed episode). 
Secondary Objective:  
1. To access the severity of the mood episodes. 
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2. To evaluate for episodes of deliberate self harm. 
3. Adherence to study treatment. 
4. Adverse effects of the medication. 
5. Global assessment of functioning. 
 
Sample size: 52 per group. Total100. 
Study volunteers / participants are (specify population group & age 
group): 18years and above. 
Location: PSGIMSR 
We request you to kindly cooperate with us in this study. We propose 
collect background information and other relevant details related to this 
study. We will be carrying out:  
Initial interview (specify approximate duration): 20-30  minutes.  
Data collected will be stored for a period of five years. We will / will not 
use the data as part of another study. 
Interview sessions: Number of sessions: 4. Approximate duration of 
each session:  
SCALES/PROFORMA USED IN OUR STUDY: 30minutes.  
Clinical examination (Specify details and purpose):  
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Blood sample collection: Specify quantity of blood being drawn: 
___________ml.  
No. of times it will be collected: _______________.  
Whether blood sample collection is part of routine procedure or for 
research (study) purpose:   
1. Routine procedure 2. Research purpose  
 
Specify purpose, discomfort likely to be felt and side effects, if any: 
_______________________________ 
 
Whether blood sample collected will be stored after study period:
 Yes / No, it will be destroyed 
Whether blood sample collected will be sold: Yes / No  
Whether blood sample collected will be shared with persons from another 
institution: Yes / No 
Medication given, if any, duration, side effects, purpose, benefits:  
Whether medication given is part of routine procedure: Yes / No (If not, 
state reasons for giving this medication) 
Whether alternatives are available for medication given: Yes / No (If not, 
state reasons for giving this particular medication) 
Final interview (specify approximate duration):_________ mts. If 
photograph is taken, purpose:  
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Benefits from this study: This study may give a lead in choosing between 
lithium and divalproate sodium in euthymic BPAD patients. hence, may 
improve the outcome of the illness. 
Risks involved by participating in this study: we do not predict any risk 
to patient as it is observational study ,as it will be decided by primary 
therapist. 
How the results will be used:  
If you are uncomfortable in answering any of our questions during the 
course of the interview / biological sample collection, you have the right 
to withdraw from the interview / study at anytime. You have the 
freedom to withdraw from the study at any point of time. Kindly be 
assured that your refusal to participate or withdrawal at any stage, if you 
so decide, will not result in any form of compromise or discrimination in 
the services offered nor would it attract any penalty. You will continue to 
have access to the regular services offered to a patient. You will NOT be 
paid any remuneration for the time you spend with us for this interview / 
study. The information provided by you will be kept in strict confidence. 
Under no circumstances shall we reveal the identity of the respondent or 
their families to anyone. The information that we collect shall be used for 
approved research purposes only. You will be informed about any 
significant new findings- including adverse events, if any, – whether 
directly related to you or to other participants of this study, developed 
during the course of this research which may relate to your willingness to 
continue participation. 
Consent: The above information regarding the study, has been read by 
me/ read to me, and has been explained to me by the investigator/s. 
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Having understood the same, I hereby give my consent to them to 
interview me. I am affixing my signature / left thumb impression to 
indicate my consent and willingness to participate in this study (i.e., 
willingly abide by the project requirements).  
 
Signature / Left thumb impression of the Study Volunteer / Legal 
Representative:  
 
Signature of the Interviewer with date:4-12-14    
  Witness: 
 
Contact number of PI:9790432213 
Contact number of Ethics Committee Office:  0422 2570170 Extn.: 5818 
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Xg;Gjy; gbtk; 
       Njjp: 
lhf;lH. rhuh mg;hpd;  Mfpa ehd;.  gp.v];.Ip kUj;Jtf; fy;Yhhpapd; kdey 
kUj;Jtj; Jiwapd; fPo; ypj;jpak; kw;Wk; ilthy;g;nuhNal; Nrhbak; Mfpa 
kdnaOr;rp NehahspfSf;fhd kdepiyia epiyg;gLj;Jk; kUe;Jfspd; 
jpwid xg;gpLk; XH tuq;fhy fz;fhdpg;G Ma;T Nkw;nfhs;s  cs;Nsd;. 
Vd; Ma;T topfhl;b : lhf;lH. I. iraj; ck;kH. cjtp NguhrphpaH  
 
Ma;tpd; Nehf;fk; :. 
1. Kjd;ik Nehf;fk; :  Nkw;$wpa Nehapd; jd;ik kPz;Lk; tUtjw;FKd;G 
mjd; ,ilg;gl;l  fhyj;ij kjpg;gpLjy; 
kdvOr;rp kw;Wk; kdj;jsHr;rp Nehapd; ntspaPLfspd; jPtpuj;ij mwpe;J 
nfhs;tJ. 
Ra jPq;F Kaw;rpfis fz;lwptJ 
Ma;tpd; rpfpr;ir tpjpKiwfis gpd;gw;WtJ. 
kUe;Jfspd; gf;f tpisTfis fz;lwptJ. 
midj;J gptpd; nray;ghL jpwid kjpg;gpLtJ  / ghpNrhjpg;gJ 
Ma;T Nkw;nfhs;tjw;fhd mbg;gil 
,ay;Gepiy Nehahspfspy; kdepiy eiyg;gLj;Jk; kUe;Jfspd; jpwid 
fz;lwpAk; Ma;T. 
ghpNrhjid vz;zpf;if  : xU FOtpw;F 52 egh;fs; nkhj;jk; : 100 
 
18 taJf;F Nky; ,Ug;gtHfs; ,jpy; NrHf;fg;gLthHfs;. 
 
Ma;T Nkw;nfhs;Sk; ,lk; : 
 
gp.v];.Ip kUj;Jtkid. Nfhak;Gj;JhH 
 
NeH fhdy; : 30 epkplq;fs; (ehd;F Kiw) 
 
 
Ma;tpd;  gyd;fs; : 
 
,e;j Ma;tpd; *yk;  ,ay;Gepiy kdj;jsHr;rp kdnaOr;rp NehahspfSf;F 
cfe;j kUe;ij NjHe;njLj;J  mjd; *yk; mtHfsJ tho;f;if juj;ij 
Nkw;gLj;jyhk;. 
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Ghjfq;fs;  / mghaq;fs; 
 
kUe;Jfs; midj;Jk; Kjd;ik rpfpr;ir NjHe;njLg;gjhy; ,e;j fz;fhdpg;G 
Ma;tpd; *yk; ve;j xU  ghjfNkh, mghaNkh Vw;glhJ. 
 
ypj;jpak; Muk;gpf;fg;gl;l kdjsHr;rp. kdvOr;rp Nehahspfis 3tJ 6 tJ 
kw;Wk; 12tJ khjk; njhlHe;J fz;fhdpf;fg;gLtH. ve;j Neuj;jpy; 
Ntz;LkhdhYk; Ma;tpypUe;J tpyfpf;nfhs;Sk; chpik cq;fSf;F cz;L. 
 
Ma;tpypUe;J tpyfpf;nfhs;tjhy; cq;fSf;F mspf;fg;gLk; rpfpr;irapy; ve;j 
tpj khw;wKk; ,Uf;fhJ. 
 
,e;j Muha;r;rpf;fhf cq;fsplk; rpy Nfs;tpfs; Nfl;fg;gLk;. NkYk; ,e;j 
Ma;tpy; gq;F nfhs;tJ cq;fs; nrhe;j tpUg;gk;. ,jpy; ve;j tpjf; 
fl;lhaKk; ,y;iy.  ePq;fs; tpUg;gg;gl;lhy; ,e;j Ma;tpd; KbTfs; 
cq;fSf;Fj; njhpag;gLj;jg;gLk;. 
 
 
Ma;thshpd; ifnahg;gk;  : 
 
Njjp      : 
 
Ma;Tf;Fl;gLgthpd; xg;Gjy; : 
 
ehd; ,e;j Muha;r;rpapd; Nehf;fk; kw;Wk; mjd; gad;ghl;bidg; gw;wp 
njspthfTk;. Tpsf;fkhfTk; njhpag;gLj;jg;glLs;Nsd;.  ,e;j Muha;r;rpapy; 
gq;F nfhs;sTk;.  ,e;j Muha;r;rpapd; kUf;Jt hPjpahd Fwpg;Gfis tUk; 
fhyj;jpYk; cgNahfglgLj;jpf; nfhs;sTk; KO kdJld; rk;kjpf;fpNwd;.    
 
 
Ma;Tf;Fl;gLgthpd;  ngaH. Kftup  :  
 
 
 
       ifnahg;gk;    : 
 
 
    Njjp    : 
 
cldpUg;gthpd;  ifnahg;gk;   : 
 
Njjp    : 
 
Ma;thshpd; njhiyNgrp vz;   : 9790432213 
 
newpKiw FO mYtyf njhiyNgrp vz; : 0422 – 2570170  cs;njhlHG 
vz;  : 581 
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SOCIODEMOGRAPHIC DETAILS & CONFOUNDING 
VARIABLES: 
Semi-structured proforma: 
A.SOCIO- DEMOGRAPHIC PROFILE: 
 OP no 
 Age 
 Sex 
 Education 
 Marital status 
 Contact number (atleast two). 
B. Confounding variables: 
 Age of onset of illness 
 Previous number of episodes 
 Previous hospitalizations 
 Polarity of episodes 
 Serum concentration of mood stabilizer 
 Dosage of mood stabilizer 
 Duration of treatment with mood stabilizer 
 Co-morbid substance dependence. 
 Confounding psychotrophics’. 
 Duration of mood stabilizer 
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ADVERSE DRUG REACTION 
1. Nausea 
2. Diarrhea 
3. Tremors 
4. Weight gain 
5. Sedation 
6. Polydipsia 
7. Polyuria 
8. Tachycardia 
9. Alopecia 
10. Any major skin lesions 
11. Hypothyroid symptoms(constipation, muscle weakness, fatigue, 
dry skin, increased sensitivity to cold). 
12. Signs of Renal dysfunction. 
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YMRS SCALE FOR MANIA: 
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HAMD SCALE FOR DEPRESSION: 
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GLOBAL ASSESSMENT OF FUNCTIONING SCALE: 
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MODIFIED SADSPERSONS SCALE: 
  
 
 
 
 
 
